Robeco Institutional Asset Management B.V. Has $1.39 Million Holdings in Hologic, Inc. $HOLX

Robeco Institutional Asset Management B.V. cut its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 74.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,330 shares of the medical equipment provider's stock after selling 63,250 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in Hologic were worth $1,390,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Victory Capital Management Inc. lifted its stake in Hologic by 34.4% in the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after buying an additional 1,692,177 shares during the period. Invesco Ltd. increased its holdings in shares of Hologic by 18.8% during the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock valued at $298,655,000 after acquiring an additional 764,573 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Hologic by 1.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider's stock valued at $276,303,000 after acquiring an additional 69,878 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Hologic by 0.8% during the first quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider's stock valued at $216,973,000 after acquiring an additional 29,133 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Hologic by 8.1% during the first quarter. Dimensional Fund Advisors LP now owns 2,838,656 shares of the medical equipment provider's stock valued at $175,331,000 after acquiring an additional 213,366 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on HOLX shares. Morgan Stanley boosted their price objective on Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. Argus boosted their price objective on Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a report on Friday, September 19th. Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Stephens reiterated an "overweight" rating and set a $78.00 price target on shares of Hologic in a report on Thursday, September 18th. Finally, Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a report on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $80.15.

Hologic Stock Up 0.6%

Shares of NASDAQ:HOLX opened at $67.73 on Wednesday. The company has a market capitalization of $15.06 billion, a PE ratio of 28.10, a price-to-earnings-growth ratio of 2.31 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The business has a fifty day moving average price of $67.03 and a two-hundred day moving average price of $63.18. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Transactions at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the company's stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.88% of the stock is owned by company insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.